Geneva-based Addex Therapeutics and funds affiliated with Perceptive Advisors, an investment management firm focused on the life sciences sector, today announced the launch of Neurosterix. With initial funding of $63 million, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development..

总部位于日内瓦的Addex Therapeutics and funds隶属于专注于生命科学领域的投资管理公司Perceptive Advisors，今天宣布推出Neurosterix。Neurosterix的初始资金为6300万美元，将从Addex收购一系列临床前资产和变构调节剂药物发现技术平台，并加速其发展。

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Today the company announced that it will contribute a portfolio of preclinical neuroscience assets and its allosteric modulator small molecule discovery technology platform to the newly founded Neurosterix SA, which is like Addex based in Geneva.

Addex Therapeutics是一家临床阶段的生物制药公司，专注于开发用于神经疾病的新型小分子变构调节剂组合。今天，该公司宣布，它将为新成立的Neurosterix SA贡献一系列临床前神经科学资产及其变构调节剂小分子发现技术平台，该公司类似于总部位于日内瓦的Addex。

Addex will retain its partnerships with Janssen Pharmaceuticals, Inc. and Indivior PLC, as well as unpartnered clinical stage assets including dipraglurant for Parkinson’s disease and post-stroke/TBI recovery as well as its preclinical GABAB positive allosteric modulator (PAM) program for chronic cough..

Addex将保留其与Janssen Pharmaceuticals，Inc.和Indivator PLC的合作伙伴关系，以及无与伦比的临床阶段资产，包括用于帕金森氏病和中风后/TBI恢复的dipraglurant，以及用于慢性咳嗽的临床前GABAB阳性变构调节剂（PAM）计划。

With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire the preclinical assets and the technology platform from Addex. In return, Addex will receive CHF5 million and a 20% equity interest in Neurosterix..

Neurosterix将从Perceptive Xontogeny Venture Fund II获得6300万美元的初始资金，并由Perceptive Life Sciences Fund和Acorn Bioventures参与，从Addex获得临床前资产和技术平台。作为回报，Addex将获得500万瑞士法郎和Neurosterix 20%的股权。

To guide the launch of Neurosterix, Tim Dyer, in addition to his role at Addex, will assume the role of CEO of Neurosterix. Lénaïc Teyssédou, Head of Finance at Addex will join Addex Executive Management. As part of the transaction, Robert Lutjens and Jean-Philippe Rocher are stepping down from Addex Executive Management to focus on their new roles as Co-Heads of Discovery at Neurosterix.

为了指导Neurosterix的推出，蒂姆·戴尔（TimDyer）除了在Addex的职位外，还将担任Neurosterix的首席执行官。Addex的财务总监莱纳伊克·泰塞杜（Lénaïc Teyssédou）将加入Addex的执行管理层。作为交易的一部分，罗伯特·卢特延斯（RobertLutjens）和让·菲利普·罗彻（Jean-PhilippeRocher）将从Addex执行管理层辞职，专注于他们作为Neurosterix发现部门联合主管的新角色。

Mikhail Kalinichev, Head of Translational Science at Addex, will also join Neurosterix in a similar role and remain a member of the Executive Management of Addex. The Neurosterix R&D leadership team will continue to support Addex through a service arrangement between the two companies..

Addex转化科学主管米哈伊尔·卡利尼切夫（MikhailKalinichev）也将加入Neurosterix担任类似职位，并仍然是Addex执行管理层的成员。Neurosterix研发领导团队将通过两家公司之间的服务安排继续支持Addex。

“The launch of Neurosterix in partnership with Perceptive is an important validation of the Addex allosteric modulator drug discovery technology platform and provides the resources to accelerate development of important preclinical assets, including the M4 PAM and mGlu7 negative allosteric modulator (NAM) programs, into the clinic,” said Tim Dyer, CEO of Addex.

“与Perceptive合作推出Neurosterix是对Addex变构调节剂药物发现技术平台的重要验证，并为加速重要临床前资产的开发提供了资源，包括M4 PAM和mGlu7阴性变构调节剂（NAM）计划，进入临床，”Addex首席执行官蒂姆·戴尔（TimDyer）说。

“This transaction significantly reduces Addex operating costs and provides CHF5 million of cash thereby extending our cash runway beyond 2026. This allows us to reach important milestones from our partnered programs, including the Phase 2 epilepsy data from our Janssen partnership in the second quarter of 2024 as well as retaining an important upside in the future of Neurosterix through our 20% equity interest.”.

“这项交易大大降低了Addex的运营成本，并提供了500万瑞士法郎的现金，从而将我们的现金跑道延长到2026年以后。这使我们能够从我们的合作项目中达到重要的里程碑，包括2024年第二季度Janssen partnership的第二阶段癫痫数据，以及通过我们20%的股权保持Neurosterix未来的重要优势。”

Allosteric modulators bind to their target receptor outside of the active site, where the natural ligand and traditional drugs operate. This non-competitive mode of action brings greater selectivity and more precision over the control of biological pathways, potentially delivering improved efficacy and safety.

变构调节剂在天然配体和传统药物起作用的活性位点之外与其靶受体结合。这种非竞争性的作用模式为生物途径的控制带来了更大的选择性和更高的精确度，有可能提高疗效和安全性。

Addex pioneered the development of high-throughput industrial-scale discovery tools for allosteric modulator drug discovery, which have delivered a broad pipeline of oral small molecule drug candidates with the potential to transform the treatment of multiple neurological disorders..

Addex率先开发了用于变构调节剂药物发现的高通量工业规模发现工具，该工具提供了广泛的口服小分子候选药物管道，有可能改变多种神经系统疾病的治疗方法。

“The team at Addex has established a leading position in allosteric modulator drug discovery at an industrial scale. The assets generated have all been validated at a preclinical level and are ready to quickly move through final stages of preparation for clinical evaluation,” said Fred Callori, Managing Director, Venture at Perceptive Advisors and Chairman of the Board of Neurosterix.

“Addex的团队在变构调节剂药物发现的工业规模上确立了领先地位。产生的资产都经过了临床前水平的验证，并准备迅速进入临床评估的最后阶段，”Perceptive Advisors风险管理董事兼Neurosterix董事会主席弗雷德·卡洛里（Fred Callori）说。

“We recognize the untapped value, not only of the assets now being developed within Neurosterix, but also the asset generating capacity of the allosteric modulator drug discovery technology platform, which with the necessary financial resources can potentially deliver transformational medicines and secure the long-term future of the company.”.

“我们认识到未开发的价值，不仅是Neurosterix目前正在开发的资产，而且变构调节剂药物发现技术平台的资产生成能力，凭借必要的财务资源，该平台有可能提供转型药物，并确保公司的长期未来。”